Eventide Asset Management LLC decreased its stake in shares of Proteostasis Therapeutics, Inc. (NASDAQ:PTI) by 50.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 108,000 shares of the company’s stock after selling 112,000 shares during the period. Eventide Asset Management LLC owned 0.43% of Proteostasis Therapeutics worth $845,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. purchased a new position in Proteostasis Therapeutics during the first quarter valued at $100,000. Dynamic Technology Lab Private Ltd purchased a new position in Proteostasis Therapeutics during the first quarter valued at $112,000. Teachers Advisors LLC boosted its position in Proteostasis Therapeutics by 26.9% in the first quarter. Teachers Advisors LLC now owns 16,007 shares of the company’s stock valued at $125,000 after buying an additional 3,390 shares in the last quarter. Trexquant Investment LP boosted its position in Proteostasis Therapeutics by 1.0% in the first quarter. Trexquant Investment LP now owns 19,790 shares of the company’s stock valued at $155,000 after buying an additional 190 shares in the last quarter. Finally, Oxford Asset Management purchased a new position in Proteostasis Therapeutics during the first quarter valued at $185,000. Institutional investors and hedge funds own 78.89% of the company’s stock.
Shares of Proteostasis Therapeutics, Inc. (PTI) traded down 0.118% during trading on Wednesday, hitting $4.245. The stock had a trading volume of 60,038 shares. The firm’s 50-day moving average is $4.32 and its 200 day moving average is $9.72. Proteostasis Therapeutics, Inc. has a 52-week low of $3.50 and a 52-week high of $20.63. The firm’s market cap is $106.30 million.
COPYRIGHT VIOLATION WARNING: “Proteostasis Therapeutics, Inc. (PTI) Shares Sold by Eventide Asset Management LLC” was posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2017/06/21/proteostasis-therapeutics-inc-pti-shares-sold-by-eventide-asset-management-llc.html.
Several equities analysts have weighed in on PTI shares. Zacks Investment Research upgraded Proteostasis Therapeutics from a “hold” rating to a “buy” rating and set a $8.50 price target for the company in a report on Wednesday, April 5th. Robert W. Baird restated an “outperform” rating and set a $13.00 price target on shares of Proteostasis Therapeutics in a report on Sunday, April 2nd.
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
Receive News & Ratings for Proteostasis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.